Utilization of expanded criteria donors in liver transplantation

International Journal of Organ Transplantation Medicine

Volumn 4, Issue 2, 2013, Pages 46-59

  Saidi, R F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIVIRUS AGENT; DOPAMINE; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; INOTROPIC AGENT; LAMIVUDINE;

CARDIOVASCULAR MORTALITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DONOR SELECTION; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; ECHOGRAPHY; EXPANDED CRITERIA DONOR; FATTY LIVER; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HYPERNATREMIA; HYPOTENSION; LIVER BIOPSY; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; REVIEW; SPLIT LIVER TRANSPLANTATION; VIRUS HEPATITIS; VIRUS INFECTION;

EID: 84876816285     PISSN: 20086490     EISSN: 20086482     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Saidi RF. Current status of liver transplantation. Arch Iran Med 2012;15:772-6.
2. Saidi RF, Markmann JF, Jabbour N, et al. The faltering solid organ donor pool in the United States (2001-2010). World J Surg 2012;36:2909-13.
3. Busuttil R.W., Tanaka K. The utility of marginal donors in liver transplantation. Liver Transplant 2003;9:651-63.
4. Attia M, Silva MA, Mirza DF. The marginal liver donor-an update. Transplant International 2008;21:713-24.
5. Angelico M. Donor liver steatosis and graft selection for liver transplantation: a short review. Eur Rev Med Pharmacol Sci 2005;9:295-7.
6. Schemmer P, Mehrabi A, Kraus T, et al. New aspects on reperfusion injury to liver-impact of organ harvest. Nephrol Dial Transplant 2004;19(S4):iv26-35.
7. Cameron AM, Ghobrial RM, Yersiz H, et al. Optimal utilization of donor grafts with extended criteria. Ann Surgery 2006;243:748-53.
8. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 2006;6:783-90.
9. Bartlett A, Heaton N. Current challenges and controversies in liver transplantation. Eur Gastroenterol Hepatol 2007;1:39-41.
10. D'Alessandro AM, Kalayoglu M, Sollinger HW, et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 1991;51:157-63.
11. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. Hepatogastroenterology 2000; 47:256-63.
12. Rinella ME, Alonso E, Rao S, et al. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transplant 2001;7:409-14.
13. Saidi RF. Change in Pattern of Organ Donation and Utilization in US. Int J Organ Transplant Med 2012;3:149-56.
14. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999;274:5692-700.
15. Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transplant 2003;9:500-5.
16. Chavin KD, Fiorini RN, Shafizadeh S, et al. Fatty acid synthase blockade protects steatotic livers from warm ischemia reperfusion injury and transplantation. Am J Transplant 2004;4:1440-7.
17. Ploeg RJ, D'Alessandro AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation- a multivariate analysis. Transplantation 1993;55:807-13.
18. Crowley H, Lewis WD, Gordon F, et al. Steatosis in donor and transplant liver biopsies. Human Pathology 2000;31:1209-13.
19. Tekin K, Imber CJ, Atli M, et al. A simple scoring system to evaluate the effects of cold ischemia on marginal liver donors. Transplantation 2004;77:411-16.
20. Briceño J, Solorzano G, Pera C. A proposal for scoring marginal liver grafts. Transplant Int 2000;13(S1):S249-S52.
21. Imber CJ, St Peter SD, Handa A, Friend PJ. Hepatic steatosis and its relationship to transplantation. Liver Transplant 2002;8:415-23.
22. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-38.
23. Urena MA, Moreno Gonzalez E, Romero CJ,et al. An approach to the rational use of steatotic donor livers in liver transplantation. Hepatogastroenterology 1999;46:1164-73.
24. Elias-Miro M, Massip-Salcedo M, Jiménez-Castro MB, Peralta C. Does adiponectin benefit steatotic liver Transplantation? Liver Transplant 2011;17:993-1004.
25. Soejima Y, Shimada M, Suehiro T, et al. Use of steatotic graft in living-donor liver transplantation. Transplantation 2003;76:344-8.
26. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73.
27. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-10.
28. Oh CK, Sanfey HA, Pelletier SJ, et al. Implication of advanced donor age on the outcome of liver transplantation. Clin Transplant 2000;14:386-90.
29. Grazi GL, Cescon M, Ravaioli M, et al. A revised consideration on the use of very aged donors for liver transplantation. Am J Transplant 2001;1:61-8.
30. Busquets J, Xiol X, Figueras J, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001;71:1765-71.
31. Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transplant 2006;12:1594-606.
32. Popper H. Aging and the liver. Progress in Liver Diseases 1986;8:659-83.
33. Serste T, Bourgeois N. Ageing and the liver. Acta Gastroenterologica Belgica 2006;69:296-8.
34. Jiménez RC, Moreno GE, Colina RF, et al. Use of octogenarian livers safely expands the donor pool. Transplantation 1999;68:572-5.
35. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301.
36. Tsukamoto I, Nakata R, Kojo S. Effect of ageing on rat liver regeneration after partial hepatectomy. Biochem Mol Biol Int 1993;30:773-8.
37. Kimura F, Miyazaki M, Suwa T, Kakizaki S. Reduction of hepatic acute phase response after partial hepatectomy in elderly patients. Res Exp Med (Berlin) 1996;196:281-90.
38. De Carlis L, Colella G, Sansalone CV, et al. Marginal donors in liver transplantation: the role of donor age. Transplant Proc 1999;31:397-400.
39. Grazi GL, Cescon M, Ravaioli M, et al. A revised consideration on the use of very aged donors for liver transplantation. Am J Transplant 2001;1:61-8.
40. Mutimer DJ, Gunson B, Chen J, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 2006;81:7-14.
41. Garcia CE, Garcia RF, Gunson B, et al. Analysis of marginal donor parameters in liver transplantation for primary biliary cirrhosis. Exp Clin Transplant 2004;2:183-8.
42. Hashimoto K, Miller C. The use of marginal grafts in liver transplantation. J Hepato-Biliary-Pancreatic Surg 2008;15:92-101.
43. Saidi RF, Bradley J, Greer D, et al. Changing pattern of organ donation at a single center: are potential brain dead donors being lost to donation after cardiac death? Am J Transplant 2010;10:2536-40.
44. Saidi RF, Elias N, Kawai T, et al. Outcome of kidney transplantation using expanded criteria donors and donation after cardiac death kidneys: realities and costs. Am J Transplant 2007;7:2769-74.
45. Axelrod DA, Schnitzler M, Salvalaggio PR, et al. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007;7:990-7.
46. Yeh H, Smoot E, Schoenfeld DA, Markmann JF. Geographic inequity in access to livers for transplantation. Transplantation 2011;91:479-86.
47. Washburn K. Geography, transplant centers, and recipients: what can we learn? Liver Transpl 2008;14:9-10.
48. Marks WH, Wagner D, Pearson TC, et al. Organ donation and utilization, 1995-2004: entering the collaborative era. Am J Transplant 2006;6:1101-10.
49. Wasshburn K, Pomfret E, Roberts J. Liver allocation and distribution: possible next steps. Liver Transpl 2011;17:1005-12.
50. Reddy S, Zilvetti M, Brockmann J, et al. Liver transplantation from non-heart-beating donors: current status and future prospects. Liver Transplant 2004;10:1223-32.
51. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart beating donors. Transplant Proc 1995;27:2893-4.
52. Muiesan P, Girlanda R, Jassem W, et al. Single-center experience with liver transplantation from controlled non-heart-beating donors: a viable source of grafts. Ann Surg 2005;242:732-8.
53. Casavilla A, Ramirez C, Shapiro R, et al. Experience with liver and kidney allografts from non-heartbeating donors. Transplantation 1995;59:197-203.
54. Manekeller S, Dobberahn V, Hirner A, Minor T. Liver integrity after warm ischemia in situ and brief preservation ex vivo: the value of aerobic postconditioning. Cryobiology 2007;55:249-54.
55. Mateo R, Cho Y, Singh G, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/ UNOS data. Am J Transplant 2006;6:791-6.
56. Otero A, Gomez-Gutierrez M, Suarez F, et al. Liver Transplantation from Maastricht category 2 non-heart-beating donors. Transplantation 2003;76:1068-73.
57. Markmann JF, Markmann JW, Markmann DA, et al. Preoperative factors associated with outcome and their impact on resource use in 1148 consecutive primary liver transplants. Transplantation 2001;72:1113-22.
58. Totsuka E, Dodson F, Urakami A, et al. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transplant Surg 1999;5:421-8.
59. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. New Engl J Med 1994;330:816-19.
60. Mimeault R, Grant D, Ghent C, et al. Analysis of donor and recipient variables and early graft function after orthotopic liver transplantation. Transplant Proc 1989;21:3355.
61. Briceño J, Marchal T, Padillo J, et al. Influence of marginal donors on liver preservation injury. Transplant 2002;74:522-6.
62. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transplant 2003;9:1053-61.
63. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transplant 2001;7:51-8.
64. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by Transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997;113:1668-74.
65. Hartwig MG, Patel V, Palmer SM, et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005;80:320-5.
66. Dodson SF, Bonham CA, Geller DA, et al. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999;68:1058-61.
67. Ho JK, Harrigan PR, Sherlock CH, et al. Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation 2006;81:129-31.
68. Nery JR, Nery-Avila C, Reddy KR, et al. Use of liver grafts from donors positive for antihepatitis Bcore antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003;75:1179-86.
69. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007;132:931-7.
70. Loggi E, Micco L, Ercolani G, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol 2012;56:579-83.
71. Saidi RF, Jabbour N, Shah SA, et al. Liver Transplantation from Hepatitis B Surface Antigen Positive Donors. Transplant Proc 2013;45:279-80.
72. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001;1:197-203.
73. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis Cpositive donors. Transplantation 2002;73:582-7.
74. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998;65:925-9.
75. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transplant 2001;7:762-8.
76. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-93.
77. Ricchiuti A, Brunati A, Mirabella S, et al. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc 2005;37:2569-70.
78. Penn I. Transmission of cancer from organ donors. Ann Transplant 1997;2:7-12.
79. Kauffman HM, McBride MA, Cherikh WS, et al. Transplant tumor registry: Donors with central nervous system tumors. Transplantation 2002;73:579-82.
80. Buell JF, Beebe TM, Trofe J, et al. Donor transmitted malignancies. Ann Transplant 2004;9:53-6.
81. Kauffman HM, Cherikh WS, McBride MA, et al. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/ united network for organ sharing update. Transplantation 2007;84:272-4.
82. Frank S, Muller J, Bonk C, et al. Transmission of glioblastoma multiforme through liver transplantation. Lancet 1998;352:31.
83. Buell JF, Trofe J, Sethuraman G, et al. Donors with central nervous system malignancies: are they truly safe? Transplantation 2003;76:340-3.
84. Urakami H, Abe Y, Grisham M. Role of reactive metabolites of oxygen and nitrogen in partial liver transplantation: lessons learned from reducedsize liver ischemia and reperfusion injury. Clin Exp Pharmacol Physiol 2007;34:912-9.
85. Couinaud C. Le Foie, Etudes Anatomiques et Chirurgicales. Paris: Masson; 1957.
86. Bismuth H, Houssin D. Reduced-sized orthotopic liver graft in hepatic transplantation in children. Surgery 1984;95:367-70.
87. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994;20:829-38.
88. Hashimoto K, Miller C. The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:92-101.
89. Ben-Haim M, Emre S, Fishbein TM, et al. Critical graft size in adult-to-adult living donor liver transplantation: impact of the recipient's disease. Liver Transpl 2001;7:948-53.
90. Marcos A, Fisher RA, Ham JM, et al. Right lobe living donor liver transplantation. Transplant 1999;68:798-803.
91. Saidi RF, Jabbour N, Li Y, et al. Is left lobe adult-toadult living donor liver transplantation ready for widespread use? The US experience (1998-2010). HPB (Oxford) 2012;14:455-60.
92. Rogiers X, Malago M, Gawad K, et al. In situ splitting of cadaveric livers. The ultimate expansion of a limited donor pool. Ann Surg 1996;224:331-9.
93. Ghobrial RM, Yersiz H, Farmer DG, et al. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg 2000;232:312-23.